吉利德科学宣布,其针对口服、每周一次给药的HIV治疗药物Islatravir与Lenacapavir的两项三期临床研究,均获得了积极的顶线结果。这一进展标志着该创新型长效治疗方案在关键性试验阶段迈出了重要一步,有望为HIV感染者的治疗管理带来新的选择。
吉利德科学宣布,其针对口服、每周一次给药的HIV治疗药物Islatravir与Lenacapavir的两项三期临床研究,均获得了积极的顶线结果。这一进展标志着该创新型长效治疗方案在关键性试验阶段迈出了重要一步,有望为HIV感染者的治疗管理带来新的选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.